INTEGRATED BIOPHARMA INC (INBP) — SEC Financial Statements & Analysis

INTEGRATED BIOPHARMA INC (INBP) is a pharmaceutical preparations company, incorporated in DE. INTEGRATED BIOPHARMA INC trades on OTC as: INBP. INTEGRATED BIOPHARMA INC (INBP)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-25. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), INTEGRATED BIOPHARMA INC carries a market cap of $5.59M, a P/E ratio of -1.97x, a P/B ratio of 0.32x, a P/S ratio of 0.13x, an enterprise value of $1.12M, and an EV/EBITDA multiple of -0.46x. On profitability, it posts a gross margin of 1.82%, an operating margin of -6.17%, a net margin of -6.48%, a Return on Equity (ROE) of -14.96%, a Return on Assets (ROA) of -11.31%, and a Return on Invested Capital (ROIC) of -16.89%. Per share, it reports EPS of $-0.09, diluted EPS of $-0.09, free cash flow per share of $0.03, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -19.28% year-over-year, net income growth of -451.73% year-over-year, and EPS growth of -443.08% year-over-year. On the balance sheet, it maintains a current ratio of 3.00x, a quick ratio of 1.42x, working capital of $11.58M, a debt-to-equity ratio of 0.43x, a debt ratio of 0.3, an interest coverage ratio of -24.15x, free cash flow of $895.00K (TTM), and net debt of $-4.47M. Figures sourced from SEC EDGAR.

Market Cap

$5.59M

P/E TTM

-1.97x

EPS TTM

$-0.09

P/B TTM

0.32x

ROE TTM

-14.96%

ROA TTM

-11.31%

Debt To Equity

0.43x

Free Cash Flow TTM

$895.00K

Net Revenue TTM Growth 1Y

-19.28%

Data as of 2026-06-30 · Source: SEC EDGAR